Capecitabine/Mitomycin versus 5-Fluorouracil/Mitomycin in Combination with Simultaneous Integrated Boost Intensity-Modulated Radiation Therapy for Anal Cancer

被引:1
|
作者
Mineur, Laurent [1 ]
Vazquez, Lea [1 ]
Belkacemi, Mohamed [2 ]
Toullec, Clemence [1 ]
Bentaleb, Newfel [1 ]
Boustany, Rania [1 ]
Plat, Frederi [1 ]
机构
[1] St Catherine Inst Canc Avignon Provence, Oncodigest & Clin Res Dept, F-84918 Avignon, France
[2] Languedoc Mutual, Stat Dept, PRECIS, Nouvelles Technol, F-34000 Montpellier, France
关键词
anal cancer; capecitabin; 5-FU; radiation therapy; toxicity; SQUAMOUS-CELL CARCINOMA; PHASE-III TRIAL; DEFINITIVE CHEMORADIATION; RANDOMIZED-TRIAL; LOCAL-CONTROL; MITOMYCIN-C; CHEMOTHERAPY; RADIOTHERAPY; FLUOROURACIL; TOXICITY;
D O I
10.3390/curroncol30090621
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Since EXTRA, a non-randomized phase II trial with 31 patients, explored the use of capecitabine, mitomycin and radiation therapy (RT) in the treatment of localized squamous cell carcinoma of the anal canal (SCCAC), this treatment has been considered as an acceptable alternative to infusional 5-FU. However, the differences in efficacy between capecitabine and 5-FU in chemoradiation therapy (CRT) with simultaneous integrated boost (SIB) radiation therapy (SIB-IMRT) for local SCCAC are not well documented. Patients included in this prospective monocentric cohort study were treated with SIB-RapidArc (a unique RT method treatment for all patients: identical technique, volume and constraints for at-risk organs), mitomycin C and 5-FU each day of RT for 7 weeks (group 1) or capecitabine each day of RT (group 2). Patients treated between July 2009 and August 2017 (group 1) and between November 2012 and April 2018 (group 2) for local SCCAC T2-4 classified as N, M0 or T, N1-3, M0 were included. Primary endpoints were progression-free survival (PFS) and acute toxicities. Results: One hundred forty-seven patients were included, 91 in group 1 and 56 in group 2. The two groups were statistically comparable in terms of sex, Eastern Cooperative Oncology Group Performance Status (ECOG PS) and TNM. With a median duration of follow-up of 53.5 months, the PFS rate at 3 years was 80% for group 1 and 75% for group 2 (p = 0.32). The 3-year colostomy-free survival rate was 92% for group 1 and 85% for group 2 (p = 0.11). The rate of patients with at least one grade 3 or higher acute toxicity was 35.5% in group 1 and 21.4% in group 2 (p = 0.10), with a trend of fewer acute toxicities with capecitabine. Conclusion: Capecitabine/mitomycin in combination with SIB RapidArc radiation therapy for anal cancer seems as effective as 5-FU-based chemotherapy and is well tolerated with minimal toxicity.
引用
收藏
页码:8563 / 8574
页数:12
相关论文
共 50 条
  • [41] Quality of life after intensity-modulated radiation therapy for anal cancer
    Tang, Yu
    Crane, Christopher H.
    Eng, Cathy
    Minsky, Bruce D.
    Delclos, Marc E.
    Krishnan, Sunil
    Malatek, Daniel
    Gould, Morris S.
    Das, Prajnan
    JOURNAL OF RADIATION ONCOLOGY, 2015, 4 (03) : 291 - 298
  • [42] Intensity-modulated radiation therapy with simultaneous integrated boost for locally advanced breast cancer: a prospective study on toxicity and quality of life
    Pasquier, David
    Le Tinier, Florence
    Bennadji, Raoudha
    Jouin, Anais
    Horn, Samy
    Escande, Alexandre
    Tresch, Emmanuelle
    Chauvet, Marie Pierre
    Mailliez, Audrey
    Crop, Frederik
    Mirabel, Xavier
    Lartigau, Eric
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [43] Phase I Study of Capecitabine, Carboplatin and Intensity-modulated Radiation Therapy for Head and Neck Cancer
    Thomas, Christopher Y.
    Read, Paul
    Petroni, Gina
    Reibel, James
    Levine, Paul A.
    ANTICANCER RESEARCH, 2009, 29 (07) : 2869 - 2876
  • [44] MITOMYCIN-C, 5-FLUOROURACIL AND RADIATION IN ADVANCED, LOCALLY RECURRENT RECTAL-CANCER
    DOBROWSKY, W
    BRITISH JOURNAL OF RADIOLOGY, 1992, 65 (770) : 143 - 147
  • [45] Capecitabine/cisplatin combined with concurrent intensity-modulated radiation therapy: a feasible therapeutic strategy for anal squamous cell carcinoma
    Li, Jielang
    Huang, Chen
    Wang, Xin
    Li, Zhiping
    Shen, Yali
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26 (03) : 739 - 746
  • [46] Comorbidities and intensity-modulated radiotherapy with simultaneous integrated boost in elderly breast cancer patients
    Alba Fiorentino
    Rosario Mazzola
    Niccolò Giaj Levra
    Sergio Fersino
    Francesco Ricchetti
    Gioacchino Di Paola
    Stefania Gori
    Alberto Massocco
    Filippo Alongi
    Aging Clinical and Experimental Research, 2018, 30 : 533 - 538
  • [47] Multiparametric MRI-guided Hypofractionated Intensity-modulated Radiation Therapy With Simultaneous Integrated Boost for Glioblastoma
    Hama, Yukihiro
    Tate, Etsuko
    ANTICANCER RESEARCH, 2022, 42 (01) : 329 - 334
  • [48] PREOPERATIVE CONCURRENT 5-FLUOROURACIL INFUSION, MITOMYCIN-C AND PELVIC RADIATION-THERAPY IN TETHERED AND FIXED RECTAL-CARCINOMA
    CHAN, A
    WONG, A
    LANGEVIN, J
    KHOO, R
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1993, 25 (05): : 791 - 799
  • [49] A randomized phase III study between sequential versus simultaneous integrated boost intensity-modulated radiation therapy in nasopharyngeal carcinoma
    Lertbutsayanukul, Chawalit
    Prayongrat, Anussara
    Kannarunimit, Danita
    Chakkabat, Chakkapong
    Netsawang, Buntipa
    Kitpanit, Sarin
    STRAHLENTHERAPIE UND ONKOLOGIE, 2018, 194 (05) : 375 - 385
  • [50] Concurrent chemoradiotherapy with 5-fluorouracil and mitomycin C for anal carcinoma: Are there differences between HIV-positive and HIV-negative patients in the era of highly active antiretroviral therapy?
    Fraunholz, Ingeborg
    Rabeneck, Daniela
    Gerstein, Johanna
    Jaeck, Katharina
    Haberl, Annette
    Weiss, Christian
    Roedel, Claus
    RADIOTHERAPY AND ONCOLOGY, 2011, 98 (01) : 99 - 104